Eagle Pharmaceuticals (EGRX) Competitors $3.55 -0.10 (-2.74%) As of 02:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EGRX vs. BIOA, CGEN, ALEC, GALT, ACOG, IKT, ALTS, KYTX, RAPT, and LXEOShould you be buying Eagle Pharmaceuticals stock or one of its competitors? The main competitors of Eagle Pharmaceuticals include BioAge Labs (BIOA), Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), Alpha Cognition (ACOG), Inhibikase Therapeutics (IKT), ALT5 Sigma (ALTS), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Eagle Pharmaceuticals vs. Its Competitors BioAge Labs Compugen Alector Galectin Therapeutics Alpha Cognition Inhibikase Therapeutics ALT5 Sigma Kyverna Therapeutics Rapt Therapeutics Lexeo Therapeutics Eagle Pharmaceuticals (NASDAQ:EGRX) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Does the media favor EGRX or BIOA? In the previous week, Eagle Pharmaceuticals and Eagle Pharmaceuticals both had 1 articles in the media. Eagle Pharmaceuticals' average media sentiment score of 0.00 equaled BioAge Labs'average media sentiment score. Company Overall Sentiment Eagle Pharmaceuticals Neutral BioAge Labs Neutral Do institutionals and insiders believe in EGRX or BIOA? 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Comparatively, 20.8% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, EGRX or BIOA? Eagle Pharmaceuticals has higher revenue and earnings than BioAge Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEagle Pharmaceuticals$257.55M0.18$35.64MN/AN/ABioAge LabsN/AN/A-$71.11MN/AN/A Is EGRX or BIOA more profitable? Company Net Margins Return on Equity Return on Assets Eagle PharmaceuticalsN/A N/A N/A BioAge Labs N/A N/A N/A SummaryEagle Pharmaceuticals beats BioAge Labs on 4 of the 4 factors compared between the two stocks. Get Eagle Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EGRX vs. The Competition Export to ExcelMetricEagle PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.10M$799.38M$5.57B$9.02BDividend YieldN/A4.84%5.25%4.03%P/E RatioN/A1.3027.1820.14Price / Sales0.18227.16417.49184.08Price / Cash0.4023.4437.0657.97Price / BookN/A6.178.085.60Net Income$35.64M-$27.58M$3.16B$248.50M7 Day Performance18.33%2.12%3.77%5.15%1 Month Performance69.05%8.39%3.90%7.62%1 Year Performance-41.23%8.05%34.22%21.56% Eagle Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EGRXEagle Pharmaceuticals2.5847 of 5 stars$3.55-2.7%N/A-39.9%$46.10M$257.55M0.00100News CoverageGap DownBIOABioAge LabsN/A$4.13-1.7%N/AN/A$150.57MN/A0.00N/ANews CoverageCGENCompugen1.4067 of 5 stars$1.78+7.2%$4.00+124.7%-5.1%$148.13M$27.86M-11.1370Positive NewsALECAlector4.0712 of 5 stars$1.40-5.4%$4.00+185.7%-65.4%$147.99M$100.56M-1.11270News CoverageGALTGalectin Therapeutics1.4075 of 5 stars$2.11-9.4%$6.00+184.4%-5.1%$147.47MN/A-2.939News CoverageGap UpACOGAlpha Cognition1.5021 of 5 stars$9.33+2.5%$20.00+114.4%N/A$145.86MN/A-7.77N/AIKTInhibikase Therapeutics1.2368 of 5 stars$1.95+20.4%$6.50+233.3%+51.2%$144.97M$260K-0.736ALTSALT5 Sigma0.0642 of 5 stars$7.24-10.9%N/AN/A$141.91M$12.53M0.00170KYTXKyverna Therapeutics1.7191 of 5 stars$3.07-6.4%$18.50+502.6%-62.2%$141.76M$7.03M-0.9196News CoveragePositive NewsRAPTRapt Therapeutics4.287 of 5 stars$8.00-5.1%$24.00+200.0%-67.2%$139.40M$1.53M-0.4280Analyst ForecastLXEOLexeo Therapeutics2.2836 of 5 stars$4.02-2.4%$16.60+312.9%-72.5%$136.77M$650K-1.2258 Related Companies and Tools Related Companies BIOA Alternatives CGEN Alternatives ALEC Alternatives GALT Alternatives ACOG Alternatives IKT Alternatives ALTS Alternatives KYTX Alternatives RAPT Alternatives LXEO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EGRX) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eagle Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eagle Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EGRX Stock Alerts